Salute e Benessere

Medical Device Engineering Market worth $20.1 billion by 2029 driven by…

Browse in-depth TOC on "Medical Device Engineering Market" Browse in-depth TOC on "Medical Device Engineering Market" 250 - Tables 50 - Figures 300 - Pages L&T Technology Services Limited: Leading Innovator in Medical Device Engineering L&T Technology Services Limited (LTTS) stands out as a top global provider of engineering services, specializing in end-to-end solutions for medical device OEMs. Known for its innovation, LTTS excels in developing cutting-edge...
PR Newswire
09/08/2024

Residential Wooden Doors Market to Reach $74.5 Billion, Globally, by 2032 at…

Prime determinants of growth Prime determinants of growth Demand in the housing market, which includes construction and renovation activities, is strongly influenced by various factors. One of the key factors is consumer preferences for wooden doors, which are determined by style, design and environmental friendliness. In addition, economic conditions such as disposable income and interest rates play a significant role in homeowners' decisions to invest in home improvements....
PR Newswire
09/08/2024

Coway Announces Financial Results for Q2 FY2024

Coway's reported earnings are as follows: Coway's reported earnings are as follows: Cumulative revenue for 2024 now stands at KRW 2,084.1 billion (+6.6% YoY) with an operating profit of KRW 404.9 billion (+9.5% YoY). InSouth Korea, domestic business generatedKRW 655.7 billionin revenue for the second quarter, making an 11.1% increase compared to the previous year. This growth is primarily attributed to the solid rental sales of both BEREX's lineup of mattresses and massage...
PR Newswire
09/08/2024

Press release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 9 August 2024 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the party listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below. Reason for notification...
Nasdaq GlobeNewswire
09/08/2024

Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Aug.08, 2024(GLOBE NEWSWIRE) --Paris, France, August 8, 2024Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of Shares OutstandingTotal number of...
Nasdaq GlobeNewswire
08/08/2024

Abzena Supplies Clinical Trial Material for Angiex's Phase I Study of AGX101, a…

Paul Jaminet, co-founder and CEO of Angiex, said: "We are very excited to have dosed our first patient in our first-in-human study of our novel TM4SF1 ADC, AGX101. Throughout the development of AGX101, Abzena has worked closely with us to achieve successful GMP manufacturing and quality control. We could not have reached this milestone without Abzena's expertise, cooperation, and support. Both companies have extensive expertise in their respective fields and an aligned mission, and we look…
PR Newswire
08/08/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 8 August 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
08/08/2024

Genmab Announces Financial Results for the First Half of 2024

August 8, 2024 Copenhagen, Denmark;Interim Report for the First Six Months Ended June 30, 2024Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio's novel antibody-drug conjugate technology platforms The U.S. Food and Drug Administration (U.S. FDA) approved EPKINLY ®(epcoritamab-bysp) for the treatment of adult patients...
Nasdaq GlobeNewswire
08/08/2024

Genmab Updates 2024 Financial Guidance

Company Announcement Genmab updates its 2024 financial guidanceIncrease in revenue driven by higher royalties and reimbursement revenueIncrease in operating profit excluding acquisition and integration charges, driven by higher revenue and focused investments COPENHAGEN, Denmark; August 8, 2024 –Genmab A/S(Nasdaq: GMAB) announced today that it is updating its 2024 financial guidance last published on May 2, 2024, following the acquisition of ProfoundBio, Inc....
Nasdaq GlobeNewswire
08/08/2024

Label-Free Detection Market worth $747 million by 2029 driven by Technological…

Browse in-depth TOC on "Label-Free Detection Market" Browse in-depth TOC on "Label-Free Detection Market" 450 - Tables54 - Figures486 - Pages Danaher Corporation: Leading Innovator in Label-Free Detection Danaher Corporation, headquartered in the US, is a top player in the global label-free detection market for 2023. Through its biotechnology division, including subsidiaries Cytiva and Pall, Danaher provides a range of label-free detection products. Although the...
PR Newswire
08/08/2024

LILYSILK Celebrates 14 Years of Elegance and Sustainability with Eco-Conscious…

Innovative Fabric Upgrades Innovative Fabric Upgrades LILYSILK has always prioritized delivering exceptional quality and elegance. This year, the brand unveils two groundbreaking fabric innovations. GOTS Certified Organic Silk sets a benchmark in luxurious fabrics, combining elegance with environmental responsibility and human safety. It exemplifies refined beauty and conscientious craftsmanship, setting a new standard in sophisticated, responsible living. Additionally,Watershine...
PR Newswire
08/08/2024

Cambridge Medical & Rehabilitation Center Accredited by The Commission on…

To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9284351-cmrc-accredited-by-commission-rehabilitation-facilities-stroke-specialty-ltac-programs/ To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9284351-cmrc-accredited-by-commission-rehabilitation-facilities-stroke-specialty-ltac-programs/ With these two new accreditations, CMRC now holds the distinction of having the highest number of CARF accreditations for...
PR Newswire
08/08/2024

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is proud to announce the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024. The EVX-01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma (skin cancer). Christian...
Nasdaq GlobeNewswire
08/08/2024

Recursion and Exscientia Enter Definitive Agreement to Create a Global…

Operational complementarities expected to yield annual synergies of approximately $100 million Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients,...
Nasdaq GlobeNewswire
08/08/2024

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of…

Pegcetacoplan also demonstrated statistical significance on the key secondary endpoints of composite renal endpoint, which combines proteinuria reduction and estimated glomerular filtration rate (eGFR) stabilisation, and proteinuria reduction of at least 50% compared to baseline, as well as nominal significance on the histological endpoint of reduction in C3c staining on kidney biopsy and stabilisation of kidney function as measured by eGFR compared to placebo. Pegcetacoplan also demonstrated...
PR Newswire
08/08/2024

Consello Capital Acquires EHE Health, the Leader in Employer-Based Preventive…

"EHE has built an excellent reputation and demonstrated its ability to partner with some of the world's largest companies. It offers a compelling value proposition in the form of bettering people's lives and consistently generates a positive return on investment for employers seeking to lower healthcare costs," said Peter Morrow, Managing Partner of Consello Capital. "We are excited to partner with the EHE team and help them continue to grow." "EHE has built an excellent…
PR Newswire
08/08/2024

Endo Presents New Data at the American Podiatric Medical Association Annual…

"We're pleased to share new data about plantar fibromatosis with healthcare providers who care for and treat patients with the condition, which can be painful and burdensome," said James P. Tursi, M.D., Executive Vice President, Global Research & Development at Endo. "Encouraged by the clinical study data being presented at APMA, we are advancing our Phase 3 clinical study to explore a potential nonsurgical option in the future." "We're pleased to share new data…
PR Newswire
08/08/2024

iTeos Reports Second Quarter 2024 Financial Results and Provides Business…

- Multiple clinical milestones across portfolio anticipated in second half of 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Pro forma cash and investment balance of $714.4 million as of June 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, Aug.08, 2024(GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage...
Nasdaq GlobeNewswire
08/08/2024

Breaking Barriers: "Salvează o inimă" Association: €200,000 for homeless people…

I felt completely helpless, I regretted not being able to do more. The idea of setting up a shelter came somehow as a saving solution for those forced to live on the streets. It was very important to buy a house. Later we found out the history of the building and we were surprised, but also impressed. The former house of Ceaușescu became a shelter for the completely helpless - a beautiful transformation!" Ionela recounts. I felt completely helpless, I regretted not being able to do more...
PR Newswire
08/08/2024

/C O R R E C T I O N -- Unilabs/

Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N's Precivity portfolio of blood tests on an exclusive basis in Europe, including Norway, Switzerland, and the United Kingdom. The agreement will also provide access in Peru, Saudi Arabia, and the United Arab Emirates. Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N'sPrecivity portfolio of blood tests on an exclusive basis inEurope, including...
PR Newswire
08/08/2024

Orion Group Half-Year Financial Report January–June 2024

ORION CORPORATIONHALF-YEAR FINANCIAL REPORT 1–6/20248 AUGUST 2024 at 12:00 EESTOrion Group Half-Year Financial Report January–June 2024Net sales totalled EUR 636.7 (January–June 2023: 567.5) million Operating profit was EUR 121.8 (102.0) millionBasic earnings per share were EUR 0.68 (0.57)Cash flow from operating activities per share was EUR 0.98 (0.27)The outlook for 2024 was upgraded after the reporting period on 1 July 2024: Net sales are estimated to be EUR 1,440...
Nasdaq GlobeNewswire
08/08/2024

WuXi Biologics and Medigene Enter into a Research Collaboration for…

"We are confident that Medigene's known capabilities in generating potential best-in-class 3S TCRs for TCR-T cell therapies can also be applied to non-cellular modalities," said Selwyn Ho, CEO of Medigene. "As such, we are delighted to be able to partner with WuXi Biologics with their validated anti-CD3 mAb, and its industry leading TCE platform and WuXiBody™ to support our strategy to apply Medigene's TCRs into new modalities, such as TCR-TCEs for use in patients where additional…
PR Newswire
08/08/2024

Orion Corporation's financial reporting and Annual General Meeting in 2025

ORION CORPORATIONSTOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 8 AUGUST 2024 at 9.45 EEST Orion Corporation's financial reporting and Annual General Meeting in 2025 Orion Corporation will publish its Financial Statement Release 2024 on Tuesday, 25 February 2025.The publication dates of the Interim Reports and the Half-Year Financial Report in 2025 are as follows: Interim Report January-March 2025Wednesday 23 April 2025Half-Year Financial Report...
Nasdaq GlobeNewswire
08/08/2024

Press Release: Sarclisa induction treatment demonstrated significantly improved…

Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplantSarclisa (isatuximab) in combination with standard-of-care lenalidomide, bortezomib, and dexamethasone (RVd) during 18-week induction treatment followed by transplant resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared to RVd induction therapy, regardless of...
Nasdaq GlobeNewswire
08/08/2024
Altri  Comunicati